Form 4: Twist Bio CEO Sells Shares for Tax Obligations
Insider Transaction Report
Twist Bioscience CEO Emily M. Leproust sold 31,379 shares of common stock to cover tax withholding obligations related to vested performance stock units.
Summary
- Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corp (TWST), reported a transaction on October 30, 2025.
- The transaction involved the sale of 31,379 shares of common stock at a price of $31.4443 per share.
- This sale was a 'sell to cover' transaction, mandated by the Issuer's equity incentive plans to satisfy tax withholding obligations for vested Performance Stock Units (PSUs), and was not a discretionary trade.
- Following this transaction, Ms. Leproust directly beneficially owns 738,809 shares of common stock.
- The filing also details various employee stock options held by Ms. Leproust, with exercise prices ranging from $5.95 to $67.85 and various vesting schedules and expiration dates.
Sentiment
Score: 5
Explanation: The transaction is a non-discretionary 'sell to cover' for tax obligations related to vested equity, which is a neutral event. It does not reflect a change in management's confidence in the company, but rather a standard administrative process for equity compensation.
Positives
- The sale was non-discretionary, specifically to cover tax withholding obligations associated with the vesting of Performance Stock Units (PSUs), indicating that the underlying PSUs had vested, often tied to performance metrics.
- The reporting person continues to hold a substantial number of shares (738,809) and significant stock options, indicating continued alignment with shareholder interests.
Negatives
- The transaction resulted in a reduction of 31,379 shares from the CEO's direct beneficial ownership.
Industry Context
This filing is an insider transaction report and does not provide information directly related to broader industry trends or competitive landscape. It reflects an individual executive's equity activity within the biotechnology sector.
Stakeholder Impact
- Shareholders: A minor reduction in the CEO's direct beneficial ownership, but the non-discretionary nature of the sale mitigates concerns about management's confidence. The CEO retains significant holdings and options.
Key Dates
| Date | Description |
|---|---|
| 09/01/2016 | 25% of shares subject to an employee stock option (exercise price $5.95) vested. |
| 09/28/2017 | 10% of shares subject to an employee stock option (exercise price $8.82) vested. |
| 09/28/2018 | 15% of shares subject to an employee stock option (exercise price $8.82) vested. |
| 10/31/2019 | 20% of shares subject to an employee stock option (exercise price $26.66) vested and became exercisable. |
| 09/01/2020 | Performance stock options (exercise price $67.85) were granted to the reporting person. |
| 10/24/2020 | 25% of shares subject to an employee stock option (exercise price $23.33) vested. |
| 12/19/2022 | Performance stock options (exercise price $67.85) vested and became exercisable due to the reporting person meeting applicable performance criteria. |
| 09/28/2025 | Expiration date for an employee stock option (right to buy) with an exercise price of $5.95. |
| 10/30/2025 | Date of common stock sale transaction. |
| 11/03/2025 | Signature date of the filing by Attorney-in-Fact. |
| 09/28/2027 | Expiration date for an employee stock option (right to buy) with an exercise price of $8.82. |
| 11/18/2028 | Expiration date for an employee stock option (right to buy) with an exercise price of $26.66. |
| 10/23/2029 | Expiration date for an employee stock option (right to buy) with an exercise price of $23.33. |
| 08/31/2030 | Expiration date for an employee stock option (right to buy) with an exercise price of $67.85. |
Recommendation
holdThe reported transaction is a routine 'sell to cover' for tax purposes, not a discretionary sale indicating a change in the CEO's outlook on the company. Such transactions are common for executives receiving equity compensation and typically do not warrant a change in investment recommendation. The CEO retains substantial equity holdings, maintaining alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate as this filing does not present new fundamental information to alter the investment thesis.
Keywords
Twist Bioscience, TWST, Emily M. Leproust, Insider Trading, Form 4, Stock Sale, CEO, Biotechnology, Synthetic Biology, Equity Incentive Plan, Performance Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.